- ...van der Linden <i>et al.</i>, 1999</a>), high solubility (Arbabi Ghahroudi M. et al, 1997) and very few cleavage sites for enzymes allow new areas of a ...el, Oliver; Wojcik, John; Kaupe, Ines; Kovacic, Boris; Wyrzucki, Arkadiusz M. et al. (2011): Targeting the SH2-kinase interface in Bcr-Abl inhibits leuk16 KB (2,252 words) - 03:24, 20 October 2016
- equipment. Finally, we thank Dr. Mark Forsyth, Dr. Helen Murphy, Dr. Bev Sher, and Dr. Doug Young for their ...<b>2.</b> Sun, Z. Z., Yeung, E., Hayes, C. A., Noireaux, V., & Murray, R. M.Linear DNA for rapid prototyping of10 KB (1,232 words) - 03:53, 20 October 2016
- ...ov, Julie E. Norville, Christopher J. Gregg, Barry L. Stoddard, and George M. Church. "Corrigendum: Biocontainment of Genetically Modified Organisms by ...r, Ph.D., Michael Rodemeyer, J.D., Michele S. Garfinkel, Ph.D., and Robert M. Friedman, Ph.D. (2014). Synthetic Biology and the US Biotechnology Regulat5 KB (662 words) - 02:05, 20 October 2016
- ...<a href="#Blank" style="padding-left: 1.8cm;" class="bgscroll" >Prof. Lars M. Blank</a></p> <b>Dr. Helen Rosenkranz</b>, for a lot of organizational work and fund administration. <48 KB (6,501 words) - 12:58, 19 October 2016
- ...ref="#Blank" style="padding-left: 1.8cm;" class="bgscroll" >Prof. Dr. Lars M. Blank</a></p> <b>Dr. Helen Rosenkranz</b>, for a lot of organizational work and fund administration. <48 KB (6,542 words) - 15:54, 3 December 2016